Ischemia-Modified Albumin as a Predictor Tissue Ischemia Marker in Patients With Acute Coronary Syndrome
DOI:
https://doi.org/10.36283/PJMD13-3/005Keywords:
Keywords: ischemia-modified albumin, ischemia-modified serum albumin, Biomarkers, Biological Marker, Oxidative Stress, Oxidative Stresses, Antioxidative Stress, Myocardial Infarction, Myocardial Infarctions, Cardiovascular StrokeAbstract
ABSTRACT:
Background: Ischemia-modified albumin (IMA) has gained attention as an important biochemical marker of oxidative stress in acute myocardial ischemia. This study assessed the screening ability of IMA in acute coronary syndrome and its correlation with the severity of obesity, arterial blood pressure, and lipid profile.
Methods: A cross-sectional study using a non-probability sampling technique with 200 patients was conducted at the Physiology Department of Liaquat University of Medical and Health Science (LUMHS) from 1st September 2021 to 1 May 2022. Obese patients from the general population who had a positive family history of cardiovascular disorders were recruited and a biophysical examination was conducted. Afterward, 5cc of blood was drawn and sent for laboratory assessment of IMA and Lipid profile by using ELISA-based assay kits. Using SPSS v.25, ANOVA and student's T-test were used to assess the quantitative data. The Chi-Square Test was employed to assess the qualitative data, and a p<0.05 was considered significant.
Results: Among 200 participants, 86 participants had increased IMA. Median body mass index (BMI), high-density lipoprotein, low-density lipoproteins, triacylglycerol, cholesterol and ischemia-modified albumin was 39.00(5.00)kg/m2, 29.00(22.25)mg/dL, 165.00(75.00)mg/dL, 189.00(94.25)mg/dL, 294.50(91.75)mg/dL and 111.00(35.00)IU/mL, respectively. A strong relationship of IMA was seen with low-density lipoproteins (r=0.608), triacylglycerol (r=0.680), and cholesterol (r=0.646). An even stronger correlation was observed between ischemia-modified albumin and both systolic and diastolic blood pressure (r=0.903 and 0.839, respectively).
Conclusion: IMA levels are altered with changes in BMI, lipid profile, and arterial blood pressure. Thus, IMA can be utilized to predict the risk of cardiovascular diseases in high-risk patients.
Keywords: Myocardial Infarction, Cardiovascular diseases, Hypertension, Oxidative stress.
References
Balamir I, Ates I, Topcuoglu C, Turhan T. Association of endocan, ischemia-modified albumin, and hsCRP levels with endothelial dysfunction in type 2 diabetes mellitus. Angiology. 2018;69(7):609-616. https://doi.org/10.1177/0003319717740781
Dervisoglu P, Oner T. Usefulness of ischemia-modified albumin for assessment of the effects of small ventricular septal defects on the pulmonary vascular bed. Cardiology in the Young. 2021;31(7):1207-1212. DOI:10.1017/S1047951121001116
Kavsak PA, Worster A, Hill SA, Jaffe AS. Evaluation of the Siemens ADVIA Centaur high-sensitivity cardiac troponin I assay in serum. Clinica Chimica Acta. 2018;487:216-221. https://doi.org/10.1016/j.cca.2018.10.012
Hakkoymaz H, Nazik S, Seyithanoğlu M, Güler Ö, Şahin AR, Cengiz E, et al. The value of ischemia-modified albumin and oxidative stress markers in the diagnosis of acute appendicitis in adults. The American journal of emergency medicine. 2019;37(11):2097-2101. https://doi.org/10.1016/j.ajem.2019.03.005
Mihara A, Ohara T, Hata J, Honda T, Chen S, Sakata S, et al. Association between serum glycated albumin and risk of cardiovascular disease in a Japanese community: The Hisayama Study. Atherosclerosis. 2020;311:52-59. https://doi.org/10.1016/j.atherosclerosis.2020.08.016
Sahin A, Turkoglu S, Tunc N, Duzenci D, Solmaz OA, Bahcecioglu IH, et al. Is ischemia-modified albumin a reliable tool for the assessment of acute pancreatitis? Therapeutics and clinical risk management. 2018:627-635. doi: 10.2147/TCRM.S162690
Marrocco I, Altieri F, Peluso I. Measurement and Clinical Significance of Biomarkers of Oxidative Stress in Humans. Oxidative Medicine and Cellular Longevity. 2017;2017:1-32. doi: 10.1155/2017/6501046
Aytac Ates H, Yücetaş U, Erkan E, Yucetas E, Ulusoy S, Kadihasanoglu M, et al. The predictive value of ischemia-modified albumin in renal ischemia-reperfusion injury. Urologia Internationalis. 2019;103(4):473-481. https://doi.org/10.1159/000500929
Acet H, Güzel T, Aslan B, Isik MA, Ertas F, Catalkaya S. Predictive value of C-reactive protein to albumin ratio in ST-segment elevation myocardial infarction patients treated with primary percutaneous coronary intervention. Angiology. 2021;72(3):244-251. https://doi.org/10.1177/0003319720963697
Gursoy AY, Caglar GS, Demirtas S. Ischemia modified albumin in perinatology. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2017;210:182-188. https://doi.org/10.1016/j.ejogrb.2016.12.022
Durankuş F, Şenkal E, Çam S, Potas N, Albayrak Y, Nural C, et al. Altered thiol/disulfide homeostasis and ischemia‐modified albumin levels in children with irritable bowel syndrome. Pediatrics International. 2021;63(3):300-305. https://doi.org/10.1111/ped.14406
Uqaili R, Memon SF, Uqaili AA, Rathore P, un Nina N, Shaikh SA. Exploring the Correlation of Ischemia-Modified Albumin, Lipid Profile, and Blood Pressure with Obesity Severity in COPD Patients: A Cross-Sectional Study at LUMHS Jamshoro. Indus Journal of Science. 2023;1(02):45-52.
Reddy VS, Pasupuleti P, Perugu B. Implications of ischemia modified albumin levels in hypertension. Asian Pacific Journal of Tropical Disease. 2015(5):S190-S1. doi: 10.1016/S2222-1808(15)60888-X
Shi W, Tang G, Zhou X, Ye Y. Appraising the Accuracy of Ischaemia-Modified Albumin in Diagnosing Stroke: A Systematic Review and Meta-Analysis. Cerebrovascular Diseases. 2021;50(4):365-370. https://doi.org/10.1159/000514382
Menon B, Ramalingam K, Krishna V. Study of ischemia modified albumin as a biomarker in acute ischaemic stroke. Annals of neurosciences. 2019;25(4):187-190. https://doi.org/10.1159/000488188
Martini S, Austin T, Aceti A, Faldella G, Corvaglia L. Free radicals and neonatal encephalopathy: mechanisms of injury, biomarkers, and antioxidant treatment perspectives. Pediatric research. 2020;87(5):823-833. https://doi.org/10.1038/s41390-019-0639-6
Galho A, Cordeiro M, Ribeiro S, Marques M, Antunes M, Luz D, et al. Protective role of free and quercetin-loaded nanoemulsion against damage induced by intracerebral haemorrhage in rats. Nanotechnology. 2016;27(17):175101. DOI 10.1088/0957-4484/27/17/175101
Bilgili S, Bozkaya G, Tütüncüler FK, Akşit M, Yavuz M. Investigation of ischemia modified albumin levels in iron deficiency anemia. Turkish Journal of Biochemistry. 2017;42(3):259-263. https://doi.org/10.1515/tjb-2016-0315
Oran I, Oran B. Ischemia-modified albumin as a marker of acute coronary syndrome: the case for revising the concept of “N-terminal modification” to “fatty acid occupation” of albumin. Disease markers. 2017;2017. DOI: 10.1155/2017/5692583
Hassan MQ, Akhtar M, Ahmed S, Ahmad A, Najmi AK. Nigella sativa protects against isoproterenol-induced myocardial infarction by alleviating oxidative stress, biochemical alterations and histological damage. Asian Pacific Journal of Tropical Biomedicine. 2017;7(4):294-299. https://doi.org/10.1016/j.apjtb.2016.12.020
Lazăr C, Vozian M, Pantea V, Mișina A, Tagadiuc O. Ischemia modified albumin in experimental ovarian torsion with and without controlled reperfusion. Revista Romana de Medicina de Laborator. 2019;27(1):43-50. https://doi.org/10.2478/rrlm-2019-0008
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Pakistan Journal of Medicine and Dentistry
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access article distributed under the terms of the CreativeCommons Attribution License (CC BY) 4.0 https://creativecommons.org/licenses/by/4.0/
How to Cite
